Antifibrinolytic
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Antifibrinolytics, such as aminocaproic acid (ε-aminocaproic acid) and tranexamic acid are used as inhibitors of fibrinolysis, which act by blocking the lysine-binding site on plasmin.
Tranexamic acid may reduce bleeding after orthopedic surgery[1]. Tranexamic acid may better than aminocaproic acid for reducing estimated blood loss in orthopedic surgery[2].
Tranexamic acid may reduce bleeding after trauma[3].
They are used in menorrhagia and bleeding tendency due to various causes.
References
- ↑ Sun Y, Jiang C, Li Q (2017). “A systematic review and meta-analysis comparing combined intravenous and topical tranexamic acid with intravenous administration alone in THA”. PLoS One. 12 (10): e0186174. doi:10.1371/journal.pone.0186174. PMC 5634626. PMID 29016673.
- ↑ Boese CK, Centeno L, Walters RW (2017). “Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty”. J Bone Joint Surg Am. 99 (19): 1621–1628. doi:10.2106/JBJS.16.00738. PMID 28976426.
- ↑ Ker K, Roberts I, Shakur H, Coats TJ (2015). “Antifibrinolytic drugs for acute traumatic injury”. Cochrane Database Syst Rev (5): CD004896. doi:10.1002/14651858.CD004896.pub4. PMID 25956410.
External links
- Antifibrinolytics at the US National Library of Medicine Medical Subject Headings (MeSH)
- Template:MeshPharmaList
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH